Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Neoadjuvant Hiltonol® (PolyICLC) for Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03262103
Recruitment Status : Recruiting
First Posted : August 25, 2017
Last Update Posted : November 2, 2018
Sponsor:
Collaborator:
Oncovir, Inc.
Information provided by (Responsible Party):
Ashutosh Kumar Tewari, Icahn School of Medicine at Mount Sinai

Tracking Information
First Submitted Date  ICMJE August 23, 2017
First Posted Date  ICMJE August 25, 2017
Last Update Posted Date November 2, 2018
Actual Study Start Date  ICMJE May 1, 2017
Estimated Primary Completion Date May 1, 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: August 23, 2017)
Dose-Limiting Toxicity level [ Time Frame: Week 6 ]
3+3 dose escalation rules to define a safe dose of preoperative intratumoral (IT) plus intramuscular (IM) Polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose (poly-ICLC, Hiltonol®) prior to radical prostatectomy
Original Primary Outcome Measures  ICMJE Same as current
Change History Complete list of historical versions of study NCT03262103 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: August 23, 2017)
  • Number of adverse events [ Time Frame: Week 6 ]
    Safety as determined by the frequency of adverse events as per the Common Terminology for Adverse Events (CTCAE) version 4.0.
  • Time to PSA progression [ Time Frame: up to Week 12 ]
    The time to prostate-specific antigen (PSA) progression will be defined as the time to PSA > 0.2 ng/mL
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Neoadjuvant Hiltonol® (PolyICLC) for Prostate Cancer
Official Title  ICMJE Phase I Study of In Situ Autologous Vaccination Against Prostate Cancer With Intratumoral and Systemic Hiltonol® (Poly-ICLC) Prior To Radical Prostatectomy
Brief Summary The purpose of this study is to test an approach of stimulating the body's immune system to attack prostate cancer. This study will test injection of a substance polylysine and carboxymethylcellulose (Poly-ICLC, Hiltonol®)through a needle guided by MRI (magnetic resonance imaging) ultrasound fusion technology into the prostate gland. Poly ICLC has been used to help the body in its fight against cancer. The first aim of the study is to determine the highest dose of a substance Poly-ICLC (Hiltonol®) that can be safely tolerated by the study participants. The second aim of the study is to find out the toxicity or side effects of poly-ICLC.
Detailed Description

This is a pilot dose escalation study of IT/IM Poly-ICLC in patients with high risk clinically localized prostate cancer. The dose and frequency of IT injections will be increased in successive cohorts to define a safe dose and schedule for further testing.

Intratumoral + intramuscular poly-ICLC in patients with clinical localized prostate cancer. In the current pilot clinical trial, poly-ICLC will be administered intratumorally (Artemis guided) and intramuscularly (e.g., deltoid muscle) prior to prostatectomy in patients with clinically localized prostate cancer. Based on the available preclinical data exploring intratumoral administration of PAMPs described above, we expect this approach will result in three immunomodulatory steps26:

Immunomodulatory Step 1: Innate immune local tumor killing induced by intratumoral poly-ICLC - the initial intratumoral injections are expected to induce activation/recruitment of IL-12, TNF-α, and other cytokines and NK cells, resulting in early tumor killing and antigen release.9-11 Poly-ICLC may also have a direct antiproliferative effect on tumor cells mediated by interferon-inducible nuclear enzyme systems.

Immunomodulatory Step 2: Th1 and cytotoxic T lymphocyte priming as a result of the repeated in-situ poly-ICLC 'danger signal' combined with the tumor antigens released in step 1 and further processed and cross-presented by poly-ICLC-activated myeloid dendritic cells.7,8 Poly-ICLC is expected to recruit myeloid dendritic cells and macrophages to the tumor site where they can load with antigens being released through the innate mechanisms, present them Th1 cells, and cross-present them to CD8 T cells in the tumor or in the regional lymph nodes, thus generating antigen specific cytotoxic T lymphocytes.

Immunomodulatory Step 3 (or "Boost" phase): Maintenance of the systemic anti-tumor immune response and migration of cytotoxic T lymphocytes to remote metastases, through repeated intramuscular poly-ICLC induction of chemokines, other costimulatory factors, and inflammasome activation.23-25 The rationale for followup with intramuscular maintenance is that as part of the comprehensive response, dsRNAs such as poly-ICLC induce various chemokines and costimulatory factors that help target the response to tumor. For example, one of these costimulatory factors is OX40, which belongs to the tumor necrosis factor family of cytokines, and helps maintain cytotoxic lymphocyte longevity and action at the tumor and metastatic sites.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Prostate Cancer
Intervention  ICMJE
  • Biological: Intratumoral (IT) Poly ICLC 0.5 mg
    0.5 mg IT once/week (week 1)
  • Biological: Intratumoral (IT) Poly ICLC 1.0 mg
    1.0 mg IT once/week (week 1)
    Other Name: Polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose
  • Biological: Intramuscular (IM) Poly ICLC
    1 mg IM twice weekly (weeks 3-6)
    Other Name: Polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose
  • Procedure: Radical Prostatectomy
    as per standard care
Study Arms  ICMJE
  • Experimental: Cohort 1
    Intratumoral (IT) Poly ICLC 0.5 mg IT once/week (week 1) Intramuscular (IM) Poly ICLC 1 mg IM twice weekly (weeks 3-6) Followed by Radical Prostatectomy at Week 10
    Interventions:
    • Biological: Intratumoral (IT) Poly ICLC 0.5 mg
    • Biological: Intramuscular (IM) Poly ICLC
    • Procedure: Radical Prostatectomy
  • Experimental: Cohort 2
    Intratumoral (IT) Poly ICLC 0.5 mg IT once/week (week 1+2) Intramuscular (IM) Poly ICLC 1 mg IM twice weekly (weeks 3-6) Followed by Radical Prostatectomy at Week 10
    Interventions:
    • Biological: Intratumoral (IT) Poly ICLC 0.5 mg
    • Biological: Intramuscular (IM) Poly ICLC
    • Procedure: Radical Prostatectomy
  • Experimental: Cohort 3
    Intratumoral (IT) Poly ICLC 1.0 mg IT once/week (week 1) Intramuscular (IM) Poly ICLC 1 mg IM twice weekly (weeks 3-6) Followed by Radical Prostatectomy at Week 10
    Interventions:
    • Biological: Intratumoral (IT) Poly ICLC 1.0 mg
    • Biological: Intramuscular (IM) Poly ICLC
    • Procedure: Radical Prostatectomy
  • Experimental: Cohort 4
    Intratumoral (IT) Poly ICLC 1.0 mg IT once/week (week 1+2) Intramuscular (IM) Poly ICLC 1 mg IM twice weekly (weeks 3-6) Followed by Radical Prostatectomy at Week 10
    Interventions:
    • Biological: Intratumoral (IT) Poly ICLC 1.0 mg
    • Biological: Intramuscular (IM) Poly ICLC
    • Procedure: Radical Prostatectomy
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: August 23, 2017)
24
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE May 1, 2020
Estimated Primary Completion Date May 1, 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Written informed consent and HIPAA authorization for release of personal health information.
  2. Age > 18 years at the time of consent.
  3. ECOG Performance Status of 0-1 within 14 days prior to being registered for protocol therapy (Study Procedure Manual).
  4. Histologically confirmed adenocarcinoma of the prostate (with previous diagnostic tissue available for tumor marker analysis).
  5. Gleason 7 - 10, cT2a - cT3b adenocarcinoma of the prostate with plans for radical prostatectomy
  6. PSA ≥ 4 ng/ml
  7. Tumor visible on multiparametric MRI
  8. Tolerated previous transrectal ultrasound guided biopsy procedure under local anesthetic

    a. Uncomplicated previous TRUS biopsy procedure (i.e., no prior hospitalization due to sepsis, prostatic abscess or severe hemorrhage following TRUS prostate biopsy)

  9. Willing to undergo the intra-tumoral (IT) injection of the Poly-ICLC into the prostatic tumor as per the protocol
  10. No prior hormonal therapy with the exception of oral 5-alpha-reductase inhibitors (finasteride, dutasteride, etc.). Patients who have received prior oral anti-androgen therapies (bicalutamide, flutamide, nilutamide, etc.) must be off treatment for at least 6 weeks prior to enrollment. Patients who have received prior LHRH agonist or antagonist therapy (leuprolide, goserelin acetate, etc.) are eligible provided serum testosterone is > 50 mg/dl.
  11. No prior radiation therapy (external beam or brachytherapy) to the pelvis or prostate.
  12. No clinically significant infections as judged by the treating investigator.
  13. No characteristics suggesting a potential higher risk of infection with intraprostatic injections:

    1. Recurrent urinary tract infections or history of prostatitis within 3 months prior to enrollment into the study.
    2. Urine analysis positive for nitrites and leucocyte esterase. Such patients could be considered for the study after treatment and resolution of the infection.
    3. Active proctitis
    4. History of prostatic abscess
    5. Taking immunosuppressive medication including systemic corticosteroids
    6. Active hematologic malignancy
  14. No uncontrolled angina, congestive heart failure or MI within 6 months.
  15. No known history of Human Immunodeficiency Virus (HIV) (HIV-1/2 antibodies), active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected).
  16. No treatment with any investigational agent for any medical condition within 28 days prior to being registered for protocol therapy.
  17. Adequate end organ function as determined by the following laboratory values:

    • White blood cell count (WBC) > 2.5 k/mm3
    • Absolute neutrophil count (ANC) > 1.5 k/mm3
    • Hemoglobin (Hgb) > 8.0 g/dL
    • Platelets > 100 k/mm3
    • Calculated creatinine clearance of > 60 cc/min using the Cockcroft-Gault formula:

    Males: (140 - Age in years) × Actual Body Weight in kg 72 × Serum Creatinine (mg/dL)

    • Bilirubin < 2.0 x ULN
    • Aspartate aminotransferase (AST) < 2.5 x ULN
    • Alanine aminotransferase (ALT) < 2.5 x ULN
  18. Able to speak, read and write in English.
Sex/Gender  ICMJE
Sexes Eligible for Study: Male
Gender Based Eligibility: Yes
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Cynthia Knauer, RN, MS 212-241-0751 cynthia.knauer@mountsinai.org
Contact: Julia Wagner 212-659-8307 julia.wagner@mountsinai.org
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03262103
Other Study ID Numbers  ICMJE GCO 15-2081
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Ashutosh Kumar Tewari, Icahn School of Medicine at Mount Sinai
Study Sponsor  ICMJE Ashutosh Kumar Tewari
Collaborators  ICMJE Oncovir, Inc.
Investigators  ICMJE
Principal Investigator: Ashutosh K. Tewari, MD Icahn School of Medicine at Mount Sinai
PRS Account Icahn School of Medicine at Mount Sinai
Verification Date November 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP